AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28281196
Drug: Inhalation via
RxNorm normalized name: propyliodone 60 % INHALATION VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation via Turbuhaler®
Trial: 28281196
Drug: Inhalation via
RxNorm normalized name: propyliodone 60 % INHALATION VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation via new dry powder inhaler (new DPI)
Trial: 28281196
Drug: Inhalation via
RxNorm normalized name: propyliodone 60 % INHALATION VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation via Spira®
Trial: 28281196
Drug: Predicted lung
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predicted lung deposited dose
Trial: 18444532
Drug: Oral captopril
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral captopril (25 mg)
Trial: 18444532
Drug: Oral nicardipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nicardipine (20 mg)
Trial: 14979419
Drug: Controllable perfusion-related
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controllable perfusion-related variables during CPB (e.g., hematocrit, mean arterial pressure, thermic perfusion, blood lactate, colloid osmotic pressure, pulsatile perfusion, acid base homeostasis, oxygenation, coated circuitry)
Trial: 10548210
Drug: PCA with
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA with a bolus of 1.5 mg piritramide and a 10-min lockout interval
Trial: 10548210
Drug: PCA combined
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA combined with nonsteroidal anti-inflammatory drugs prescribed three times per day
Trial: 1899325
Drug: Theophylline (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (250 mg three or four times a day)
Trial: 22149452
Drug: Potassium supplementation
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium supplementation (100 mmol daily)
Trial: 18635722
Drug: Venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venlafaxine XR 75-225 mg/day
Trial: 8915561
Drug: Fluoxetine 20-60
RxNorm normalized name: fluoxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20-60 mg/day
Trial: 7673949
Drug: Chlorambucil (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorambucil (0.1 mg/kg/day orally for 12 months)
Trial: 2169778
Drug: Granisetron (40-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (40-200 micrograms/kg, 30 min infusion)
Trial: 2169778
Drug: Granisetron (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (160 micrograms/kg, 3 min infusion)
Trial: 28197938
Drug: Taohong Siwu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taohong Siwu Decoction (TSD) plus oral prednisone
Trial: 28197938
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus oral prednisone
Trial: 29231407
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication (methotrexate)
Trial: 22459966
Drug: Eritoran 4
RxNorm normalized name: Perftoran component perfluorodecalin
DrugBank: Perfluorodecalin (DB16292)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eritoran 4 mg
Trial: 17242095
Drug: Eritoran 12
RxNorm normalized name: Perftoran component perfluorodecalin
DrugBank: Perfluorodecalin (DB16292)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eritoran 12 mg
Trial: 17242095
Drug: Eritoran 28
RxNorm normalized name: Perftoran component perfluorodecalin
DrugBank: Perfluorodecalin (DB16292)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eritoran 28 mg
Trial: 22459966
Drug: Eritoran (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eritoran (all doses)
Trial: 20855800
Drug: Palifermin (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palifermin (180 µg per kg of body weight) administered intravenously as a single dose 3 days before each chemotherapy cycle (maximum, 6 cycles)
Trial: 18249119
Drug: Chemotherapy (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (various agents and schedules)
Trial: 18249119
Drug: Chemotherapy clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy clinical trial
Trial: 18249119
Drug: Chemotherapy in
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy in patients over 60 years
Trial: 12915290
Drug: Olanzapine 5-15
RxNorm normalized name: olanzapine 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 5-15 mg daily
Trial: 16918641
Drug: Topical vitamin
RxNorm normalized name: vitamin A Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical vitamin E
Trial: 6374682
Drug: miconazole/hydrocortisone preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: miconazole/hydrocortisone preparation
Trial: 6374682
Drug: nystatin/benzalkonium chloride/dimethicone/hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nystatin/benzalkonium chloride/dimethicone/hydrocortisone preparation
Trial: 2876035
Drug: Latamoxef 6g
RxNorm normalized name: latamoxef
DrugBank: Latamoxef (DB04570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Latamoxef 6g daily for 7 days
Trial: 2876035
Drug: Latamoxef 3g
RxNorm normalized name: latamoxef
DrugBank: Latamoxef (DB04570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Latamoxef 3g daily for 7 days
Trial: 26538525
Drug: Tenofovir alafenamide
RxNorm normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tenofovir alafenamide group (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir alafenamide 10 mg)
Trial: 20420113
Drug: Ginger (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger (1 gram of dried powder suspended in 100 ml water)
Trial: 15659136
Drug: Steroid avoidance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid avoidance (SA) with basiliximab, cyclosporine (CsA), and mycophenolate mofetil (MMF)
Trial: 30265586
Drug: Steroid avoidance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid avoidance (SA)
Trial: 15659136
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with steroids tapered to 5 mg prednisone/d by day 30
Trial: 2997387
Drug: Intranasal high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal high-dose interferon
Trial: 2997387
Drug: Intranasal low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal low-dose interferon
Trial: 25236994
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (sunitinib)
Trial: 22358993
Drug: TACE with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TACE with multiple anticancer drugs (epirubicin, cisplatin, mitomycin C, 5-fluorouracil)
Trial: 20163368
Drug: Ranibizumab 0.3
RxNorm normalized name: RANIBIZUMAB 0.3MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.3 mg (Group B)
Trial: 20163368
Drug: Ranibizumab 0.5
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.5 mg (Group B)
Trial: 17403436
Drug: Single-agent and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent and combined treatments
Trial: 17403436
Drug: Metformin (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (n = 6)
Trial: 16234141
Drug: Intravaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravaginal misoprostol (50 mug every 6 h for a maximum of two doses)
Trial: 16234141
Drug: Intracervical Foley
RxNorm normalized name: eladocagene exuparvovec
DrugBank: Eladocagene exuparvovec (DB16780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracervical Foley balloon catheter (for 12 h followed by intravenous oxytocin infusion)
Trial: 12163990
Drug: Selective lymph
RxNorm normalized name: Bos taurus lymph preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective lymph node dissection after hyperfractionated accelerated radio-(chemo-)therapy
Trial: 12163990
Drug: Hyperfractionated accelerated
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperfractionated accelerated radio-(chemo-)therapy
Trial: 10793877
Drug: Disodium pamidronate
RxNorm normalized name: Disodium pamidronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium pamidronate 300 mg/day for 4 weeks every 16 weeks (group A)
Trial: 10793877
Drug: Disodium pamidronate
RxNorm normalized name: Disodium pamidronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium pamidronate 150 mg/day for 4 weeks every 8 weeks (group B)
Trial: 8992677
Drug: Observation period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation period of 22 months with cladribine treatment
Trial: 3841315
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg intrathecal morphine
Trial: 3841315
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg intrathecal morphine
Trial: 26143234
Drug: 4 mm
RxNorm normalized name: potassium 8.4 MMOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mm mini-tablet
Trial: 26143234
Drug: syrup
RxNorm normalized name: Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: syrup
Trial: 18507107
Drug: suspension
RxNorm normalized name: Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suspension
Trial: 26143234
Drug: joint administration
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: joint administration with food or drink
Trial: 23520237
Drug: Weekly telephone
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly telephone contact (substudy)
Trial: 21878843
Drug: Mifepristone 200
RxNorm normalized name: mifepristone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 200 mg orally for up to 12 weeks
Trial: 18543496
Drug: Rehabilitation training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitation training therapy alone (Control)
Trial: 12969104
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion containing ropivacaine (1 mg.ml‐1), fentanyl (2 micro g.ml‐1), and epinephrine (2 micro g.ml‐1) for group RFE.
Trial: 12969104
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion without epinephrine for group RF.
Trial: 10717247
Drug: 120FEC (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120FEC (120 mg/m2 of epirubicin)
Trial: 10717247
Drug: 60FEC (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60FEC (60 mg/m2 of epirubicin)
Trial: 9443096
Drug: VPA monotherapy
RxNorm normalized name: VPA
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VPA monotherapy
Trial: 2868163
Drug: L-carnitine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine supplementation
Trial: 8112200
Drug: DHEP plasters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEP plasters (diclofenac hydroxyethylpyrrolidine), 180 mg each, applied b.i.d. for 15 days
Trial: 3524418
Drug: Amoxicillin-clavulanic acid
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanic acid (250 mg amoxicillin and 125 mg clavulanic acid) administered every 8 h for 10 days
Trial: 3524418
Drug: Cefaclor (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor (250 mg) administered every 8 h for 10 days
Trial: 26552835
Drug: Noxipoint therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noxipoint therapy (NT)
Trial: 26552835
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy including transcutaneous electrical nerve stimulation (PT‐TENS)
Trial: 26552835
Drug: NT-like treatments
RxNorm normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-like treatments
Trial: 23668887
Drug: DTP booster
RxNorm normalized name: DTP-348
DrugBank: DTP-348 (DB12741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTP booster vaccine
Trial: 20583934
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose methotrexate
Trial: 20583934
Drug: Multiple dose
RxNorm normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose methotrexate
Trial: 18218147
Drug: Magnesium treatment
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium treatment (500 mg divided into two tablets for 8 weeks)
Trial: 16247548
Drug: Therapeutic education
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic education plus conventional pharmacological treatment
Trial: 16247548
Drug: Conventional pharmacological
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional pharmacological treatment only
Trial: 14615149
Drug: FSME-IMMUN "new"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSME-IMMUN "new" vaccine 0.6 microg
Trial: 14615149
Drug: FSME-IMMUN "new"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSME-IMMUN "new" vaccine 1.2 microg
Trial: 14615149
Drug: FSME-IMMUN "new"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSME-IMMUN "new" vaccine 2.4 microg
Trial: 8706313
Drug: Pretreatment (before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretreatment (before treatment with methimazole)
Trial: 8706313
Drug: Treated (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treated (after 11.2 ± 1.0 weeks treatment with methimazole)
Trial: 8706313
Drug: Propranolol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (20 mg thrice daily for 2 days)
Trial: 7800160
Drug: Cocaine (60-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (60-80 mg)
Trial: 3050587
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Cyclosporin A and Azathioprine)
Trial: 29145345
Drug: Other antispastic
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antispastic drug + Lokomat Training
Trial: 21159143
Drug: Three courses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three courses of platinum-based chemotherapy
Trial: 21159143
Drug: Six courses
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Six courses of platinum-based chemotherapy
Trial: 21159143
Drug: Chemotherapy use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy use in a national population
Trial: 18337042
Drug: Weight-adjusted dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-adjusted dose of 1.75 ml/kg
Trial: 18337042
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose of 120 ml of non-ionic contrast material (320 mg/ml)
Trial: 15332395
Drug: OK-432 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OK-432 and 30 mg of doxorubicin
Trial: 11293552
Drug: Fluvastatin XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin XL 80 mg HS
Trial: 11293552
Drug: Fluvastatin IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin IR 40 mg HS
Trial: 2312775
Drug: Metoprolol CR/ZOK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol CR/ZOK 100 mg once daily
Trial: 2312775
Drug: Conventional Metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Metoprolol Tablets (CT) 100 mg once daily
Trial: 2312775
Drug: Conventional Metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Metoprolol Tablets (CT)
Trial: 25231029
Drug: SLActive implants
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLActive implants
Trial: 21121960
Drug: SLA implants
RxNorm normalized name: slash pine pollen extract
DrugBank: Pinus elliottii pollen (DB10747)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLA implants
Trial: 26288392
Drug: Grape juice
RxNorm normalized name: grape juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape juice (10 mL/(kg·min) for 28 days)
Trial: 25138784
Drug: Lornoxicam (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam (8 mg)
Trial: 12930432
Drug: Tolterodine (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine (twice daily for 16 weeks)
Trial: 8697160
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg lisinopril
Trial: 7039760
Drug: Rosaramicin 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosaramicin 250 mg six hourly for seven days
Trial: 7039760
Drug: Tetracycline 250
RxNorm normalized name: tetracycline 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline 250 mg six hourly for seven days
Trial: 31456562
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy (7 sessions)
Trial: 31456562
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy (7 sessions)
Trial: 29422473
Drug: Preoperative antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative antibiotics at the time of admission
Trial: 29422473
Drug: Perioperative antibiotics
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative antibiotics at the time of induction of general anesthesia
Trial: 27247220
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with cisplatin/paclitaxel followed by neoadjuvant radiochemotherapy (RCT) to 45 Gy (1.5 Gy twice per day concurrent cisplatin/vinorelbine)
Trial: 22963812
Drug: NCX 4016
RxNorm normalized name: NCX 701
DrugBank: NCX 701 (DB05409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NCX 4016 (800 mg, twice daily)
Trial: 20372668
Drug: Tutoring peers
RxNorm normalized name: BEER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tutoring peers in oral health (Part 2)
Trial: 18357917
Drug: Cytokine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytokine therapy using colony-stimulating factors (CSF) for bone marrow mobilisation
Trial: 18357917
Drug: Local injection
RxNorm normalized name: Sclerosing agents for local injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local injection of monocyte chemoattractant protein 1 (MCP-1)
Trial: 18357917
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bone marrow mobilisation and MCP-1 injection
Trial: 11711509
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of amiloride and spironolactone
Trial: 10333091
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (100 mg coenzyme Q10, 600 mg ascorbic acid, 270 mg alpha-tocopherol)
Trial: 2268915
Drug: Ginseng‐Rhizome saponin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginseng‐Rhizome saponin (GRS) 50 mg per tablet, three times a day for two months
Trial: 6856487
Drug: Diflunisal 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal 1,000 mg
Trial: 3468226
Drug: Propoxyphene napsylate
RxNorm normalized name: Propoxyphene Napsylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propoxyphene napsylate 100 mg
Trial: 6856487
Drug: Acetaminophen with
RxNorm normalized name: acetaminophen with codeine ORAL ELIXIR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen with codeine 60 mg
Trial: 6856487
Drug: Propoxyphene with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propoxyphene with 100 mg
Trial: 26955675
Drug: Porous tantalum
RxNorm normalized name: tantalum
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Porous tantalum rod combined with Gugutou Huaisiyu Capsule (GHC)
Trial: 20308663
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of docetaxel, bevacizumab, thalidomide, and prednisone
Trial: 12975277
Drug: Radioactive tracer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioactive tracer (10 mCi of technetium 99m‐labeled macroaggregated albumin in 10 mL of physiologic saline)